Stellate Ganglion Block Access for PTSD

Full Title:
TREAT PTSD Act

Summary#

This bill requires the Department of Veterans Affairs (VA) and the Department of Defense (DoD) to provide stellate ganglion block (SGB) as a treatment option for people with post‑traumatic stress disorder (PTSD). It applies to enrolled veterans and to service members and reservists enrolled in TRICARE who have a PTSD diagnosis and choose to receive SGB after being told the risks and benefits. The bill also requires the VA and DoD to update their joint clinical guideline for PTSD to show SGB as an option and list clinical indicators and contraindications.

  • Main change: VA and DoD must offer SGB to eligible, enrolled veterans and TRICARE beneficiaries with PTSD who elect the treatment after informed decision-making.
  • How it can be given: Through VA/DoD medical facilities or through outside providers who participate in VA or TRICARE programs.
  • Guideline update: The VA/DoD PTSD clinical practice guideline must be updated within 180 days to reflect SGB as an option and describe when it should or should not be used.
  • Effective timing: The new rules for providing SGB take effect 180 days after the bill becomes law.
  • What is unclear: The bill does not specify limits on number of treatments, exact provider qualifications, payment rates, reporting or outcomes monitoring, or detailed eligibility beyond diagnosis and enrollment.

(Brief definition) A stellate ganglion block is an injection near a bundle of nerves in the neck intended to interrupt certain nerve signals; it is used in some settings to reduce symptoms linked to the body's stress response.

What it means for you#

  • Veterans enrolled in VA care: If you are enrolled and have a PTSD diagnosis, the VA must offer you SGB as a treatment option if you choose it after being told the risks and benefits. The procedure may be done at a VA facility or by an outside provider approved under VA rules.
  • Active duty, reserve members, and TRICARE enrollees: If you are enrolled in TRICARE and have PTSD, DoD/TRICARE must offer SGB under the same informed‑consent rules.
  • Health care providers in VA/DoD or TRICARE: Providers may be asked to offer or refer for SGB and follow the updated PTSD guideline. The bill refers to “qualified” providers but does not define specific credentialing.
  • Families and caregivers: More treatment options may become available for people with PTSD, subject to local availability of trained providers and facilities.
  • VA and DoD administrators: Must update clinical guidance within 180 days, and set up access pathways (in‑house or contracted) to provide SGB to eligible patients.

Expenses#

No publicly available information.

  • The bill itself does not include a fiscal estimate in the text provided.
  • This could increase VA and DoD health care spending for the procedure, related supplies, provider payment, and any contracting with outside providers.
  • It could also require administrative work to update guidelines, train clinicians, and arrange provider networks or scheduling.
  • The size and timing of any new costs are not specified in the bill text.

Proponents' View#

  • The bill appears intended to increase access to an additional treatment option for PTSD by making SGB available to veterans and service members enrolled in VA or TRICARE.
  • Supporters may argue that including SGB in the joint VA/DoD guideline will standardize when and how the procedure is used.
  • Making SGB available through both department facilities and participating outside providers could expand geographic access for patients.

Opponents' View#

  • One concern is that the bill does not set standards for how often SGB can be given, who exactly is qualified to perform it, or how to monitor safety and long‑term outcomes.
  • The bill does not include a fiscal note, so it is unclear how much the VA and DoD will need to spend to implement this mandate and how that will affect other services.
  • The requirement to add SGB to the guideline and offer it within 180 days may be a short timeline for training, credentialing, and contracting.
  • The bill does not require data collection or reporting on effectiveness, so it may be hard to track whether expanding access improves patient outcomes.